Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harry Herr

Showing results (11-20 of 65) with videos related to

Pageof 7
Sort By:
Urology Practice|April 27, 2023
Does Antimicrobial Prophylaxis in Patients With Specific Comorbidities Reduce the Risk of Infection After Simple Cystourethroscopy? LetterHarry Herr
Urology|June 25, 2026
Low-Grade, Papillary Bladder Tumors A plea for in-office fulgurationHarry Herr
Urology|May 10, 2019
Preventable Cancer Deaths Associated with Bladder Preservation for Muscle Invasive Bladder CancerHarry Herr
Urology|September 3, 2022
WITHDRAWN: Neoadjuvant Chemotherapy and Bladder-Sparing Surgery for Muscle-Invasive Bladder Cancer: Ten-year OutcomesHarry Herr
European Urology Oncology|November 11, 2020
Improving the Quality of Transurethral Resection of Bladder Tumor: Urologist, Audit ThyselfHarry Herr
Urology Practice|June 24, 2024
De-Escalation of Therapy for Low-Grade Papillary Bladder Tumors With Preserved Long-Term Oncologic OutcomesHarry Herr
BJU International|June 5, 2009
Should all patients receive single chemotherapeutic agent instillation after bladder tumour resection?Jakub Dobruch, Harry Herr
Urology|November 5, 2021
Cisplatin, Neoadjuvant Chemotherapy and Bladder CancerHarry Herr, Mark Soloway
JAMA|July 6, 2006
NMP22 and surveillance for recurrent bladder cancerScott Eggener, Harry Herr
Arab Journal of Urology|November 19, 2015
Is 'second-look' (re-staging) transurethral resection of bladder tumours a new standard of care?Harry Herr, Guido Dalbagni
Pageof 7

Showing results (11-20 of 65) with videos related to

Sort By:
Pageof 7
Urology Practice|April 27, 2023
Does Antimicrobial Prophylaxis in Patients With Specific Comorbidities Reduce the Risk of Infection After Simple Cystourethroscopy? LetterHarry Herr
Urology|June 25, 2026
Low-Grade, Papillary Bladder Tumors A plea for in-office fulgurationHarry Herr
Urology|May 10, 2019
Preventable Cancer Deaths Associated with Bladder Preservation for Muscle Invasive Bladder CancerHarry Herr
Urology|September 3, 2022
WITHDRAWN: Neoadjuvant Chemotherapy and Bladder-Sparing Surgery for Muscle-Invasive Bladder Cancer: Ten-year OutcomesHarry Herr
European Urology Oncology|November 11, 2020
Improving the Quality of Transurethral Resection of Bladder Tumor: Urologist, Audit ThyselfHarry Herr
Urology Practice|June 24, 2024
De-Escalation of Therapy for Low-Grade Papillary Bladder Tumors With Preserved Long-Term Oncologic OutcomesHarry Herr
BJU International|June 5, 2009
Should all patients receive single chemotherapeutic agent instillation after bladder tumour resection?Jakub Dobruch, Harry Herr
Urology|November 5, 2021
Cisplatin, Neoadjuvant Chemotherapy and Bladder CancerHarry Herr, Mark Soloway
JAMA|July 6, 2006
NMP22 and surveillance for recurrent bladder cancerScott Eggener, Harry Herr
Arab Journal of Urology|November 19, 2015
Is 'second-look' (re-staging) transurethral resection of bladder tumours a new standard of care?Harry Herr, Guido Dalbagni
Pageof 7